Combining popular diabetes drugs offers complementary heart and kidney benefits, research finds

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes. The findings were published today in The Lancet Diabetes & Endocrinology and presented in May at the 61st European Renal Association Congress in Stockholm…